- Home
- PLRX vs IMUX Comparison
PLRX vs IMUX Comparison
Compare PLRX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- IMUX
- Stock Information
- Founded
- PLRX 2015
- IMUX 2016
- Country
- PLRX United States
- IMUX United States
- Employees
- PLRX N/A
- IMUX N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- IMUX Health Care
- Exchange
- PLRX Nasdaq
- IMUX Nasdaq
- Market Cap
- PLRX 89.0M
- IMUX 90.4M
- IPO Year
- PLRX 2020
- IMUX N/A
- Fundamental
- Price
- PLRX $1.64
- IMUX $0.82
- Analyst Decision
- PLRX Hold
- IMUX Strong Buy
- Analyst Count
- PLRX 10
- IMUX 5
- Target Price
- PLRX $3.93
- IMUX $7.50
- AVG Volume (30 Days)
- PLRX 972.5K
- IMUX 1.1M
- Earning Date
- PLRX 08-07-2025
- IMUX 08-07-2025
- Dividend Yield
- PLRX N/A
- IMUX N/A
- EPS Growth
- PLRX N/A
- IMUX N/A
- EPS
- PLRX N/A
- IMUX N/A
- Revenue
- PLRX N/A
- IMUX N/A
- Revenue This Year
- PLRX N/A
- IMUX N/A
- Revenue Next Year
- PLRX N/A
- IMUX N/A
- P/E Ratio
- PLRX N/A
- IMUX N/A
- Revenue Growth
- PLRX N/A
- IMUX N/A
- 52 Week Low
- PLRX $1.10
- IMUX $0.56
- 52 Week High
- PLRX $16.10
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- PLRX 56.62
- IMUX 40.85
- Support Level
- PLRX $1.40
- IMUX $0.85
- Resistance Level
- PLRX $1.70
- IMUX $0.96
- Average True Range (ATR)
- PLRX 0.11
- IMUX 0.07
- MACD
- PLRX 0.00
- IMUX -0.01
- Stochastic Oscillator
- PLRX 77.78
- IMUX 10.00
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.